Immunogenicity and safety of tixagevimab-cilgavimab for COVID-19 pre-exposure prophylaxis in immunocompromised 20 to <40 kg children and adolescents: A pilot, prospective, open-labeled study

• Main Authors: Jassada Buaboonnam (Author), Supattra Rungmaitree (Author), Nuntawan Piyaphanee (Author), Sirirat Charuvanij (Author), Onsiri Pitisuttithum (Author), Katherine Copeland (Author), Chatkamol Pheerapanyawaranun (Author), Laddawan Jansarikit (Author), Suvimol Niyomnaitham (Author), Kulkanya Chokephaibulkit (Author)
• Format: Book
• Published: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

We evaluated the immunogenicity of 300 mg Tixagevimab-Cilgavimab in immunocompromised children and adolescents who weighed 20 to >40 kg. Six to 18-year-old participants were divided into two groups by body weight and received 300 mg (20 to <40 kg) and 600 mg (≥40 kg) Tixagevimab-Cilgavimab, re...